Literature DB >> 26461145

Cell(s) of Origin of Langerhans Cell Histiocytosis.

Matthew Collin1, Venetia Bigley1, Kenneth L McClain2, Carl E Allen3.   

Abstract

Langerhans cell histiocytosis (LCH) is heterogeneous disease characterized by common histology of inflammatory lesions containing Langerin(+) (CD207) histiocytes. Emerging data support a model in which MAPK activation in self-renewing hematopoietic progenitors may drive disseminated high-risk disease, whereas MAPK activation in more differentiated committed myeloid populations may induce low-risk LCH. The heterogeneous clinical manifestations with shared histology may represent the final common pathway of an acquired defect of differentiation, initiated at more than one point. Implications of this model include re-definition of LCH as a myeloid neoplasia and re-focusing therapeutic strategies on the cells and lineages of origin.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF; Dendritic cell; Langerhans cell histiocytosis; MAPK signaling; Myeloid differentiation

Mesh:

Year:  2015        PMID: 26461145      PMCID: PMC4699587          DOI: 10.1016/j.hoc.2015.06.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  86 in total

1.  IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia.

Authors:  Yaming Wang; Kristy J Szretter; William Vermi; Susan Gilfillan; Cristina Rossini; Marina Cella; Alexander D Barrow; Michael S Diamond; Marco Colonna
Journal:  Nat Immunol       Date:  2012-06-24       Impact factor: 25.606

2.  BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis.

Authors:  Felix Sahm; David Capper; Matthias Preusser; Jochen Meyer; Albrecht Stenzinger; Felix Lasitschka; Anna-Sophie Berghoff; Antje Habel; Marion Schneider; Andreas Kulozik; Ioannis Anagnostopoulos; Leonhard Müllauer; Gunhild Mechtersheimer; Andreas von Deimling
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

3.  Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders.

Authors:  Kudakwashe Chikwava; Ronald Jaffe
Journal:  Pediatr Dev Pathol       Date:  2004-11-08

4.  A novel role for Notch ligand Delta-1 as a regulator of human Langerhans cell development from blood monocytes.

Authors:  Natsuki Hoshino; Naoyuki Katayama; Tetsunori Shibasaki; Kohshi Ohishi; Junji Nishioka; Masahiro Masuya; Yoshihiro Miyahara; Masahiko Hayashida; Daiki Shimomura; Takuma Kato; Kaname Nakatani; Kazuhiro Nishii; Kagemasa Kuribayashi; Tsutomu Nobori; Hiroshi Shiku
Journal:  J Leukoc Biol       Date:  2005-07-21       Impact factor: 4.962

5.  Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.

Authors:  Stephen S Chung; Eunhee Kim; Jae H Park; Christopher Y Park; Omar Abdel-Wahab; Young Rock Chung; Piro Lito; Julie Teruya-Feldstein; Wenhuo Hu; Wendy Beguelin; Sebastien Monette; Cihangir Duy; Raajit Rampal; Leon Telis; Minal Patel; Min Kyung Kim; Kety Huberman; Nancy Bouvier; Michael F Berger; Ari M Melnick; Neal Rosen; Martin S Tallman
Journal:  Sci Transl Med       Date:  2014-05-28       Impact factor: 17.956

6.  Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells.

Authors:  D Strunk; K Rappersberger; C Egger; H Strobl; E Krömer; A Elbe; D Maurer; G Stingl
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

7.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

8.  The origin and kinetics of mononuclear phagocytes.

Authors:  R van Furth; Z A Cohn
Journal:  J Exp Med       Date:  1968-09-01       Impact factor: 14.307

9.  Expansion of regulatory T cells in patients with Langerhans cell histiocytosis.

Authors:  Brigitte Senechal; Gaelle Elain; Eric Jeziorski; Virginie Grondin; Natacha Patey-Mariaud de Serre; Francis Jaubert; Kheira Beldjord; Arielle Lellouch; Christophe Glorion; Michel Zerah; Pierre Mary; Mohammed Barkaoui; Jean Francois Emile; Liliane Boccon-Gibod; Patrice Josset; Marianne Debré; Alain Fischer; Jean Donadieu; Frederic Geissmann
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069

10.  Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis.

Authors:  Nicola E Annels; Cristiana E T Da Costa; Frans A Prins; Annemieke Willemze; Pancras C W Hogendoorn; R Maarten Egeler
Journal:  J Exp Med       Date:  2003-05-12       Impact factor: 14.307

View more
  23 in total

1.  BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor.

Authors:  Rosemarie Mastropolo; Allison Close; Steven W Allen; Kenneth L McClain; Scott Maurer; Jennifer Picarsic
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Authors:  Matthias Papo; Fleur Cohen-Aubart; Ludovic Trefond; Adeline Bauvois; Zahir Amoura; Jean-François Emile; Julien Haroche
Journal:  Curr Oncol Rep       Date:  2019-05-21       Impact factor: 5.075

3.  The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.

Authors:  Leomar Y Ballester; Miguel D Cantu; Karen P H Lim; Stephen F Sarabia; Lizmery Suarez Ferguson; C Renee Webb; Carl E Allen; Kenneth L McClain; Carrie A Mohila; Jyotinder N Punia; Angshumoy Roy; Dolores H López-Terrada; M John Hicks; Kevin E Fisher
Journal:  Hematol Oncol       Date:  2017-02-20       Impact factor: 5.271

4.  Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases.

Authors:  Fabio Facchetti; Stefano Aldo Pileri; Luisa Lorenzi; Valentina Tabanelli; Lisa Rimsza; Stefania Pittaluga; Stephan Dirnhofer; Christiane Copie-Bergman; Laurence de Leval; Andreas Rosenwald; Andrew Wotherspoon; Falko Fend
Journal:  Virchows Arch       Date:  2017-07-10       Impact factor: 4.064

5.  Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report.

Authors:  Leonie Frauenfeld; Irina Bonzheim; Stefan Wirths; Julia Steinhilber; Marius Horger; Barbara Mankel; Wolfgang Bethge; Falko Fend; Birgit Federmann
Journal:  Virchows Arch       Date:  2019-07-17       Impact factor: 4.064

6.  Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.

Authors:  Paul Milne; Venetia Bigley; Chris M Bacon; Antoine Néel; Naomi McGovern; Simon Bomken; Muzlifah Haniffa; Eli L Diamond; Benjamin H Durham; Johannes Visser; David Hunt; Harsha Gunawardena; Mac Macheta; Kenneth L McClain; Carl Allen; Omar Abdel-Wahab; Matthew Collin
Journal:  Blood       Date:  2017-05-16       Impact factor: 22.113

7.  A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility.

Authors:  Erin C Peckham-Gregory; Rikhia Chakraborty; Michael E Scheurer; John W Belmont; Harshal Abhyankar; Amel G Sengal; Brooks P Scull; Olive Eckstein; Daniel J Zinn; Louisa Mayer; Albert Shih; Miriam Merad; D Williams Parsons; Kenneth L McClain; Philip J Lupo; Carl E Allen
Journal:  Blood       Date:  2017-09-21       Impact factor: 22.113

8.  Atypical presentation of isolated orbital Langerhans cell histiocytosis.

Authors:  Nikisha Q Richards; Matthew Young; Kasey Pierson; John Le; Yuan Rong
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

9.  Pulmonary Manifestations of GATA2 Deficiency.

Authors:  Beatriz E Marciano; Kenneth N Olivier; Les R Folio; Christa S Zerbe; Amy P Hsu; Alexandra F Freeman; Armando C Filie; Michael A Spinner; Lauren A Sanchez; Jana P Lovell; Mark Parta; Jennifer M Cuellar-Rodriguez; Dennis D Hickstein; Steven M Holland
Journal:  Chest       Date:  2021-06-03       Impact factor: 10.262

10.  Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells.

Authors:  Karen Phaik Har Lim; Paul Milne; Michael Poidinger; Kaibo Duan; Howard Lin; Naomi McGovern; Harshal Abhyankar; Daniel Zinn; Thomas M Burke; Olive S Eckstein; Rikhia Chakraborty; Amel Sengal; Brooks Scull; Evan Newell; Miriam Merad; Kenneth L McClain; Tsz-Kwong Man; Florent Ginhoux; Matthew Collin; Carl E Allen
Journal:  Blood Adv       Date:  2020-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.